US 10130658
Method of ex vivo enhancement of immune cell activity for cancer immunotherapy with a small molecule ablative compound
granted A61KA61K2239/38A61K2239/57
Quick answer
US patent 10130658 (Method of ex vivo enhancement of immune cell activity for cancer immunotherapy with a small molecule ablative compound) held by Provectus Pharmatech, Inc. expires Mon Nov 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Provectus Pharmatech, Inc.
- Grant date
- Tue Nov 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 26
- CPC classes
- A61K, A61K2239/38, A61K2239/57, A61K31/352, A61K38/1709